---
title: CDMO Daily News — September 4, 2026
slug: daily-news-2026-09-04-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: September 4 CDMO daily: Cellipont Bioservices Advances Six Cell Therapy Programs to 2026 IND Submissions; Northway Biotech Opens €61M Cell Therapy CDMO in…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-09-04-cdmo
published_at: 2026-09-04T23:59:58.929Z
last_updated: 2026-09-05T00:01:38.631Z
---

### [Cellipont Bioservices](/companies/cellipont-bioservices) Advances Six Cell Therapy Programs to 2026 IND Submissions
- Cellipont's Texas facility is supporting six client cell therapy projects targeting IND submissions in 2026.
- The CDMO provides integrated process development, GMP manufacturing, analytical testing, and regulatory preparation for autologous and allogeneic programs.

**Operational Impact**

Cellipont's six concurrent IND-stage programs signal expanded cell therapy manufacturing capacity and regulatory readiness at its Texas facility, relevant for sponsors evaluating CDMO partners for near-term clinical advancement.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/cellipont-bioservices-supports-six-cell-therapy-projects-targeting-2026-ind-submissions)*

---

### [Northway Biotech](/companies/northway-biotech) Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- [Northway Biotech](/companies/northway-biotech) inaugurated a 3,500-square-meter cGMP facility in Vilnius, Lithuania, backed by €61 million investment from Northway Group.
- The center operates up to 20 independent cGMP manufacturing lines for autologous and allogeneic [cell therapies](/companies/celltherapies), personalized vaccines, and regenerative medicine.
- Facility begins operations with first customers and contracts already secured; supports biotech, pharma, university hospitals, and research institutions.

**Operational Impact**

Northway's Vilnius facility adds dedicated cell-therapy and regenerative-medicine cGMP capacity in Eastern Europe, offering CDMO directors a new regional option for autologous/allogeneic cell manufacturing and personalized vaccine development with segregated multi-product infrastructure.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/northway-biotech-opens-70-94m-cell-therapy-cdmo-in-lithuania)*

## References

1. [PharmaSource RSS — [Cellipont Bioservices](/companies/cellipont-bioservices) Advances Six Cell Therapy Programs to 2026 IND Submissions](https://pharmasource.global/content/news/cdmo-news/cellipont-bioservices-supports-six-cell-therapy-projects-targeting-2026-ind-submissions)
2. [PharmaSource RSS — Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines](https://pharmasource.global/content/news/cdmo-news/northway-biotech-opens-70-94m-cell-therapy-cdmo-in-lithuania)

Source: https://www.cdmo.directory/posts/daily-news-2026-09-04-cdmo